Continuous glucose monitors (CGMs) are monitoring devices people with diabetes use. They apply them directly to the skin and ...

The FDA designated Abbott's recall of FreeStyle Libre 3 sensors as the most serious, class I type due to the risk for ...

Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

A CGM helps me run marathons and do epic bike rides better than ever.

During her time at CNET, Kim Wong-Shing loved demystifying the world of wellness to make it accessible to any reader. She was also passionate about exploring the intersections of health, history ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

A few weeks ago, an allergist prescribed a two-week course of an oral steroid to clear up my sinus inflammation. Before I ...

CEO Robert Ford said in an earnings call in October that the potential for Abbott's FreeStyle Libre CGM is a “mass market opportunity.” There are about 10 million CGM users worldwide ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.